Profound Medical reports Q2 EPS (52c), consensus (40c)

Reports Q2 revenue $2.21M, consensus $4.73M. “The second quarter was characterized by some unfortunate timing, as we experienced what we believe are short-term delays in completing a few TULSA-PRO capital sales,” said Arun Menawat, Profound’s CEO and chairman. “Had these occurred in the quarter, total revenues would have been over $3 million. With this, combined with our large and growing TULSA-PRO system capital sales pipeline, and the strong TULSA procedure volume growth we are seeing, we continue to work towards achieving total year-over-year revenue growth at an approximate range of 70% to 75% in 2025.”